FDA-Cleared AI Diagnostic Software

FDA-cleared AI diagnostic software refers to AI-enabled medical software that has gone through an FDA device pathway for a specific intended use. The phrase is important, but it is often used too loosely. FDA clearance is not a blanket statement that the software can diagnose anything, work in every patient population, or replace clinician judgment. It applies to the cleared device function and intended use.

For buyers, the practical question is not only whether a product is FDA-cleared. The practical question is what was cleared, for whom, using what input, in which setting, and with what limitations.

Clearance, Approval, and Intended Use

Many AI-enabled diagnostic products enter the market through 510(k) clearance, De Novo classification, or other FDA pathways depending on risk and predicate status. In everyday conversation, people often say FDA-approved when they mean FDA-cleared. That distinction matters in regulatory language, but the most important buyer issue is intended use.

Intended use defines what the product is meant to do. A tool cleared to flag one imaging finding in adults should not be treated as a general diagnostic engine. A tool cleared for one modality, population, or workflow may not be appropriate outside that scope.

The FDA AI-Enabled Medical Devices List

FDA maintains a public page for AI-enabled medical devices to support transparency. It is a useful starting point for understanding the market and identifying device functions, but it is not a complete purchasing analysis. FDA has also stated that the public list is not comprehensive, so buyers should verify product details directly through FDA records and vendor documentation.

Clinical leaders should review the device name, company, submission number, specialty, date, and publicly available summary where applicable. They should also ask the vendor for intended use, indications, limitations, user instructions, performance data, and update policies.

Clinical Decision Support Boundary

Not all diagnostic-related AI software is regulated the same way. FDA clinical decision support guidance clarifies when certain software functions may be excluded from the device definition and when FDA digital health policies continue to apply. This matters for tools that organize, recommend, rank, or interpret clinical information.

If a vendor says the product is not FDA-regulated, the buyer should still ask why. The answer should be tied to intended use and function, not vague language about being only informational.

What FDA Status Does Not Solve

FDA status does not replace local validation, workflow review, privacy review, training, or monitoring. A cleared AI product may still perform differently in a local setting because of patient mix, scanner protocol, data quality, EHR integration, user behavior, or version changes. FDA transparency principles for machine learning-enabled medical devices emphasize information needed for safe and effective use. That information still has to be operationalized by the health system.

Questions to Ask Vendors

• What exact device function and intended use were cleared?
• Which population, modality, and setting are in scope?
• What FDA pathway and submission number apply?
• What warnings, limitations, and contraindications are documented?
• How are software updates, model changes, and version history handled?
• What evidence supports local acceptance testing and monitoring?
• What workflow steps remain the clinician's responsibility?

How to Use FDA Clearance in Evaluation

FDA clearance should be treated as an important evidence and transparency signal, not as the end of evaluation. It tells the buyer that a specific device function went through an FDA pathway. It does not answer every clinical, operational, privacy, equity, or financial question.

The safest procurement process pairs regulatory review with evidence review, local workflow testing, data governance, clinician training, and post-deployment monitoring.

Related AI Diagnostics Topics

• How to Evaluate an AI Diagnostic Platform
• AI Diagnostics Accuracy and Limitations
• FDA and Regulation
• Medical Imaging FDA-Cleared AI
• How Hospitals Evaluate Clinical AI Vendors

Reviewed: August 6, 2026. Next review: November 6, 2026.